Decoy Therapeutics (DCOY) Accumulated Expenses (2014 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Accumulated Expenses of $244456.0 for Q1 2026, down 64.81% year-over-year from $694625.0 in Q1 2025, and down 71.63% quarter-over-quarter from $861748.0 in Q4 2025.
Decoy Therapeutics (DCOY) Accumulated Expenses (2014 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Accumulated Expenses for 13 consecutive years, with $244456.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 64.81% year-over-year to $244456.0; the TTM figure through Mar 2026 stood at $244456.0 (down 64.81% YoY), while the FY2025 annual figure was $861748.0, up 144.52% from the prior year.
- Accumulated Expenses slipped to $244456.0 in Q1 2026 per DCOY's latest filing, from $861748.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.4 million in Q4 2022 and bottomed at $244456.0 in Q1 2026.
- Historically, Accumulated Expenses has averaged $742558.5 across 5 years, with a median of $740553.0 in 2025.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 331.05% — and 2023, when it tumbled 71.11%.
- Decoy Therapeutics' Accumulated Expenses stood at $1.4 million in 2022, then sank by 71.11% to $406745.0 in 2023, then slipped by 13.36% to $352419.0 in 2024, then soared by 144.52% to $861748.0 in 2025, then slumped by 71.63% to $244456.0 in 2026.
- Business Quant data shows DCOY's Accumulated Expenses at $244456.0 in Q1 2026, $861748.0 in Q4 2025, and $744783.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215,697.00 |
| Mar 31, 2026 | 244,456.00 |
| Dec 31, 2025 | 861,748.00 |
| Sep 30, 2025 | 744,783.00 |
| Jun 30, 2025 | 740,553.00 |
| Mar 31, 2025 | 694,625.00 |
| Dec 31, 2024 | 352,419.00 |
| Sep 30, 2024 | 439,931.00 |
| Jun 30, 2024 | 535,418.00 |
| Mar 31, 2024 | 403,309.00 |
| Dec 31, 2023 | 406,745.00 |
| Sep 30, 2023 | 772,794.00 |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 985,393.00 |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 1.39 Mn |
| Jun 30, 2022 | 895,106.00 |
| Mar 31, 2022 | 390,233.00 |
| Dec 31, 2021 | 567,787.00 |
| Sep 30, 2021 | 323,364.00 |